Core Viewpoint - The company has terminated its collaboration agreement with Axion, regaining global rights to certain drug candidates, including IMM2510 and IMM27M, which target PD-L1 and CTLA-4 respectively [1] Group 1: Agreement Details - The company has granted Axion exclusive rights for research, development, and commercialization of several dual-specific antibodies targeting PD-L1 and VEGF, as well as monoclonal antibodies targeting CTLA-4 [1] - A termination agreement has been established, which reverts all previously granted licenses back to the company, while allowing Axion a limited license to gradually conclude its clinical development activities [1] Group 2: Financial Implications - The termination of the agreement will not affect the $35 million in upfront and milestone payments already received from Axion [1] Group 3: Future Outlook - The company expresses confidence in the therapeutic potential of IMM2510 and IMM27M and is committed to accelerating the clinical development of these assets [1]
宜明昂科-B(01541)重获IMM2510及IMM27M的全球权利